Awaiting The Two To Tango: Pharma Innovation And Public Health Interest

“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform – Balancing Affordability with Incentives for Innovation’, … Continue reading

Replication of ‘Old Paradigm’ of the developed pharmaceutical markets is unlikely to yield results in the evolving new paradigm of India

“Health leaps out of science and draws nourishment from the society around it” – Gunnar Myrdal (Swedish Nobel Laureate Economist) The success concoction of the global pharmaceutical industry for India, by and large, still remains to be sustained attempts in … Continue reading